Further Victory For Celltrion and Teva, As Their Trastuzumab Biosimilar, Herzuma, Receives FDA Approval

 
• By Dean Rudge
  
Archery
Bullseye for Celltrion and Teva, as they bag trastuzumab and rituximab approvals in quick succession. • Source: Shutterstock

More from Biosimilars

More from Products